1.Clinical follow-up study of SARS-CoV-2 Omicron infection
Xiaoyu KANG ; Lin ZHANG ; Liangliang WANG ; Rui YAN ; Jiuping WANG ; Zhangqian CHEN
Shanghai Journal of Preventive Medicine 2024;36(1):25-29
ObjectiveTo observe the clinical course and explore the risk factors for SARS-CoV-2 RNA negative conversion duration (NCD) in asymptomatic and mild-symptomatic patients infected with the SARS-CoV-2 Omicron variant. MethodsClinical data were collected from 244 confirmed cases of corona virus disease (COVID-19) with Omicron variant infection admitted to a temporal makeshift hospital in Shanghai from April 9, 2022 to May 20, 2022. Demographic and clinical data were analyzed, with a primary focus on the time of COVID-19 nucleic acid conversion. Univariate and multivariate Cox regression analysis were used to determine identify risk factors associated with NCD. ResultsThe median duration of negative RNA conversion was 9 days (ranged 7‒12 days). The percentage of patients with positive nucleic acid results on the 5th, 7th, 10th, and 14th days after confirmed infection was 68.4%, 47.1%, 20.1%, and 5.7%, respectively. Kaplan-Meier curves indicated a median nucleic acid conversion time of 12 days (ranged 10‒14 days) for patients with hypertension, 9 days (ranged 7‒11 days) in patients without hypertension, and 11 days (ranged 9‒13 days) for patients aged ≥60 years, and 9 days (ranged 7‒11 days) for patients aged <60 years. Multivariate Cox regression analysis showed that only hypertension was an independent risk factor of NCD (RR=1.60; 95% CI: 1.03‒2.49, P=0.036). ConclusionIn asymptomatic or mildly symptomatic patients infected with the Omicron variant, 20.1% patients continue to exhibit positive viral nucleic acid on the 10th days of infection. The independent risk factor associated with the conversion of SARS-CoV-2 nucleic acid to negative is hypertension.
2.Meta-analysis of risk factors for multi-drug resistant organisms infections after liver transplantation
Jin YANG ; Na HUI ; Jiuping WANG ; Qiao CHENG ; Meixia ZHANG
Chinese Journal of Modern Nursing 2024;30(29):3980-3986
Objective:To systematically evaluate influencing factors of multi-drug resistant organisms (MDROs) infection in patients undergoing liver transplantation and to provide reference for infection prevention and control.Methods:The relevant literatures on the influencing factors of MDROs infection after liver transplantation included in PubMed, Medline, Embase, Wed of Science, China Biology Medicine disc, Wanfang Database, China National Knowledge Infrastructure and VIP were searched by computer, and the search time was from the establishment of databases to September 1, 2023. The languages were limited to Chinese and English. Two evaluators screened literature and extracted data, and used The Newcastle Ottawa Scale to evaluate the quality of the final included literature. Meta-analysis was performed using RevMan5.4 software.Results:Finally, a total of 17 literatures were included, including five case-control studies and 12 cohort studies. The results of Meta-analysis showed that ClassⅡ toⅣ hepatic encephalopathy, renal insufficiency, colonization of drug-resistant organisms before transplantation, performing tracheal intubation, tracheal intubation time greater than or equal to 48 h, tracheal intubation time greater than or equal to 72 h, length of ICU stay, use of antibiotics before transplantation, postoperative bile leakage, postoperative fungal culture of positivity, reoperation after transplantation and hemodialysis were risk factors for MDROs infection after liver transplantation ( P<0.05) . Conclusions:There are many influencing factors for multi-drug resistant organisms infection in liver transplant patients after surgery. Medical staff should be vigilant and identify relevant risk factors, conduct infection risk assessment and take preventive and control measures based on risk factors to improve the prognosis of liver transplant patients.
3.Efficacy and safety of the 12-week sofosbuvir-coblopasvir regimen in treatment of chronic hepatitis C
Wei ZHANG ; Song ZHAI ; Hong DU ; Fuchun JING ; Limei WANG ; Ye ZHANG ; Bibo KANG ; Jiuping WANG ; Shuangsuo DANG ; Jianqi LIAN ; Hong JIANG
Journal of Clinical Hepatology 2023;39(3):539-545
Objective To investigate the efficacy and safety of the 12-week regimen with sofosbuvir and coblopasvir hydrochloride in the treatment of chronic hepatitis C (CHC) in northwest China. Methods This study enrolled 101 patients with CHC of any genotype who received sofosbuvir (400 mg) combined with coblopasvir hydrochloride (60 mg) for 12 weeks in The First Affiliated Hospital of Air Force Medical University, The Second Affiliated Hospital of Air Force Medical University, The Second Affiliated Hospital of Xi'an Jiaotong University, and Baoji Central Hospital from July 1 to December 31, 2021, among whom 13 had liver cirrhosis and 88 did not have live cirrhosis. Other antiviral drugs such as ribavirin were not added regardless of the presence or absence of liver cirrhosis or the genotype of CHC. Related clinical data ere extracted, including HCV RNA quantification and liver biochemical parameters at baseline, at week 12 of treatment, and at 12 weeks after drug withdrawal. The primary endpoints were sustained virologic response at 12 weeks after the end of treatment (SVR12) and safety at week 12 of treatment, and the secondary endpoint was the effect of the 12-week treatment on liver biochemical parameters. The non-normally distributed continuous data were expressed as M ( P 25 - P 75 ), and the Mann-Whitney U test was used for comparison between groups. Results A total of 101 patients were included in the analysis, among whom there were 55 male patients (54.5%) and 46 female patients, and the median age was 53 years. Among these patients, 12.8% had liver cirrhosis, 1.0% had liver cancer, 3.0% were treatment-experienced patients, and 3.0% had type 2 diabetes. As for genotype distribution, 8% had CHC genotype 1, 60% had CHC genotype 2, 19% had CHC genotype 3, and 6% had CHC genotype 6, and genotype was not tested for 7% of the patients. After 12 weeks of treatment, all 101 patients had a HCV RNA level of below the lower limit of detection and an SVR12 rate of 100%, with a significant reduction in the serum level of alanine aminotransferase (ALT) from baseline to week 12 of treatment ( P < 0.05). Among these patients, 22.7% had concomitant medications such as atorvastatin calcium, aspirin, metformin, nifedipine, bicyclol, and compound glycyrrhizin. The incidence rate of adverse events was 16.8%, and fatigue (12.9%) was the most common adverse event. Conclusion The 12-week treatment with sofosbuvir and coblopasvir hydrochloride can obtain high SVR12 in CHC patients in northwest China and has good antiviral safety, with a significant improvement in abnormal serum ALT at week 12 of treatment.
4.Small molecule inhibitors of RORγt for Th17 regulation in inflammatory and autoimmune diseases
Jiuping ZENG ; Mingxing LI ; Qianyun ZHAO ; Meijuan CHEN ; Long ZHAO ; Shulin WEI ; Huan YANG ; Yueshui ZHAO ; Anqi WANG ; Jing SHEN ; Fukuan DU ; Yu CHEN ; Shuai DENG ; Fang WANG ; Zhuo ZHANG ; Zhi LI ; Tiangang WANG ; Shengpeng WANG ; Zhangang XIAO ; Xu WU
Journal of Pharmaceutical Analysis 2023;13(6):545-562
As a ligand-dependent transcription factor,retinoid-associated orphan receptor γt(RORyt)that controls T helper(Th)17 cell differentiation and interleukin(IL)-17 expression plays a critical role in the pro-gression of several inflammatory and autoimmune conditions.An emerging novel approach to the therapy of these diseases thus involves controlling the transcriptional capacity of RORyt to decrease Th17 cell development and IL-17 production.Several RORyt inhibitors including both antagonists and inverse agonists have been discovered to regulate the transcriptional activity of RORyt by binding to orthosteric-or allosteric-binding sites in the ligand-binding domain.Some of small-molecule inhibitors have entered clinical evaluations.Therefore,in current review,the role of RORyt in Th17 regulation and Th17-related inflammatory and autoimmune diseases was highlighted.Notably,the recently developed RORyt inhibitors were summarized,with an emphasis on their optimization from lead compounds,ef-ficacy,toxicity,mechanisms of action,and clinical trials.The limitations of current development in this area were also discussed to facilitate future research.
5.Chinese herbal medicines for treating ulcerative colitis via regulating gut microbiota-intestinal immunity axis.
Yifei YANG ; Yi WANG ; Long ZHAO ; Fang WANG ; Mingxing LI ; Qin WANG ; Haoming LUO ; Qianyun ZHAO ; Jiuping ZENG ; Yueshui ZHAO ; Fukuan DU ; Yu CHEN ; Jing SHEN ; Shulin WEI ; Zhangang XIAO ; Xu WU
Chinese Herbal Medicines 2023;15(2):181-200
Ulcerative colitis (UC) is one of types of inflammatory bowel disease with high recurrence. Recent studies have highlighted that microbial dysbiosis as well as abnormal gut immunity are crucial factors that initiate a series of inflammatory responses in the UC. Modulating the gut microbiota-intestinal immunity loop has been suggested as one of key strategies for relieving UC. Many Chinese herbal medicines including some of single herb, herbal formulas and the derived constituents have been reported with protective effect against UC through modulating gut microbiome and intestinal immunity. Some clinical trials have shown promising results. This review thus focused on the current knowledge on using Chinese herbal medicines for treating UC from the mechanism aspects of regulating intestinal homeostasis involving microbiota and gut immunity. The existing clinical trials are also summarized.
6.Epidemiological characteristics and influencing factors of 245 COVID⁃19 cases in Shaanxi Province in 2020
Zecheng LI ; Jixu ZHU ; Lin ZHANG ; Jiuping WANG ; Zhangqian CHEN
Shanghai Journal of Preventive Medicine 2022;34(7):655-659
ObjectiveTo determine the epidemiological characteristics of COVID-19 in Shaanxi Province. MethodsEpidemiological analysis was conducted on the confirmed cases of COVID-19 (n=245) from January 23rd, 2020 through February 21st, 2020 based on the official data announced by Shaanxi Province. The effects of local population migration, prevention and control measures on the epidemic were explored. ResultsAs of February 21st, 2020, a total of 245 COVID-19 cases had been notified in Shaanxi Province, with a cumulative incidence rate of 0.63 per 100 000, of which imported cases accounted for 47.34%. The high incidence was observed between January 31st and February 5th. Xi’an had the largest number of COVID-19 cases, followed by Ankang, Hanzhong and Xianyang, totally accounting for 81.20% of the cases in the province. In terms of social factors, daily morbidity was positively correlated with Baidu migration scale index 14 days before. On January 25th, the provincial health emergency response was launched, and on January 31st, it was further upgraded for quarantine. On February 20th, the provincial prevention and control system was implemented by classified areas. There were no emerging local cases after February 21st and no confirmed cases for 28th consecutive days as of March 19th. Local cases and close contacts were cleared to zero on March 27th. ConclusionThe COVID-19 epidemic in Shaanxi Province is mainly concentrated in Guanzhong area and southern Shaanxi, with a widespread pattern in all cities. The prevention and control measures have effectively contained the epidemic, with a declining incidence. However, quarantine of suspected cases and close contacts remains crucial for routine prevention and control strategy.
7.Development strategy of cancer hospitals under normalized epidemic prevention and control based on a PEST analysis
Fanghui GU ; Xiyao ZHONG ; Jianying WANG ; Jiuping GUAN ; Xinqiang JI ; Dong XUE ; Jiafu JI
Chinese Journal of Hospital Administration 2021;37(1):15-20
Objective:To explore the external factors of the development of cancer hospitals under normalized epidemic prevention and control, and to propose targeted strategies in accordance with existing practice.Methods:PEST model was used to analyze the political, economic, social and technological environment of specialized cancer hospitals, with an overall strategy proposed based on the specific analysis of a cancer hospital.Results:In the era of normalized epidemic prevention and control, cancer hospitals were facing a new environment that was common or unique to other types of medical institutions. In response, the case hospital had adopted such strategies as integrating prevention and control with medical services, integrating offline with online services, and integrating internal and external resources to promote its recovery and development.Conclusions:Cancer hospitals and government should fully leverage the environmental changes incurred by the normalization of prevention and control, and formulate a more integrated development strategy covering short, medium up to long term conditions, based on the two major objectives of epidemic prevention and control and cancer prevention and medical services.
8.Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study
Qiang XU ; Wei ZHANG ; Yuxiu MA ; Caini HE ; Liting ZHANG ; Yilihamu ABULITIFU ; Yu LI ; Nan WANG ; Hongli WANG ; Yunyu ZHAO ; Xu GAO ; Peigen GAO ; Xingyang SU ; Shen LI ; Yuanyuan LIU ; Feng GUO ; Zhangqian CHEN ; Hailing LIU ; Xiaoqin GAO ; Jianjun FU ; Guoying YU ; Xiaozhong WANG ; Jiuping WANG ; Yongping ZHANG ; Fanpu JI
Chinese Journal of Hepatology 2021;29(11):1046-1052
Objective:To study the real-world outcome of China FDA-approved Sofosbuvir (SOF)/Velpatasvir (VEL) in Northwest China.Methods:In this multicenter, prospective, real-world cohort study, we recruited patients from 10 sites from Northwest China, who were chronically infected with HCV GTs 1-6 from 06/2018 to 09/2019. Patients received SOF (400mg)/VEL (100mg) for 12 weeks, and with ribavirin 900-1200 mg for GT3 cirrhosis and for any genotype decompensated cirrhosis. The primary endpoint was sustained virological response at 12-weeks post-treatment (SVR12) and safety. The secondary endpoint was the change of liver function after the achievement of SVR12.Results:Totally, 143 patients were enrolled in the study, four patients were lost to follow-up and one died during the follow-up, 138 patients were included in per-protocol analysis. Of the 138 patients, the mean age 53 years, 53.6% male, 94.2% Han nationality, 53.6% liver cirrhosis, 10.1% HBsAg +, 6.5% renal dysfunction, 5.1% treatment-experienced, and 16.7% patients received ribavirin treatment. The genotype distribution was as follows: 35.5% GT1, 42.8% GT2, 15.9% GT3, and 5.8% un-typed. The SVR12 rate was 96.5% (138/143, 95% CI: 93.5%-99.6%) for intention-to-treat analysis, and in per-protocol analysis, all 138 patients obtained SVR12 (100%). Compared with baseline, the serum total bilirubin, ALT and AFP levels decreased (all P < 0.05), as well as increased ALB and platelet count (all P < 0.001) at post-treatment 12-weeks. Overall adverse events (AEs) rate is 29.0%, and the most common AEs were anemia (14.5%) and fatigue (8.0%). Severe side effects (edema and fatigue) occurred in 2 patients, one of whom needed a short-term interruption of treatment due to fatigue. Conclusion:In this real-world cohort study, 12-week SOF/VEL regimen with or without ribavirin achieved high SVR12 rates (96.5%-100% overall) with excellent safety profile among patients with HCV GT1/2/3 infection including patients with GT3 and cirrhosis, and led to improvement of liver function.
9.Related factors of aggressive behavior among school aged children in Nanjing
Yao WANG ; Kangkang CHU ; Bin XU ; Jiuping ZHANG ; Chenyang WANG ; Hui FANG ; Bing ZOU ; Gongkai JIAO ; Qingxiang LIU ; Min ZHANG ; Li GU ; Xiaoyan KE
Chinese Mental Health Journal 2018;32(1):37-42
Objective:To study the distribution and related factors of aggressive behavior among school aged children in Nanjing.Methods:Totally 4678 primary school students in Nanjing were sampled by cluster random sampling in this study.The General questionnaire and Achenbach's child Behavior Checklist were used to investi gate the general situation and aggressive behavior.Results:The rate of aggressive behavior of school-age children in Nanjing was 3.6 % (167/4678).Multivariate logistic regression analysis indicated that democratic parenting style [other parenting styles (OR =1.94,95% CI =1.10-3.42),mixed parenting style(OR =1.96,95% CI =1.35-2.85)],and genetic screening before birth (OR =0.71,95% CI =0.52-0.99) were protective factors for children's aggressive behavior.The factor figures of aggressive behavior were positively correlated with that of oth er behavior problems in Pearson correlation analysis (r =0.52-0.80,Ps <0.01).Conclusion:About 3.6% of the school aged children in Nanjing have aggressive behavior.It is more likely to have aggressive behaviors for children who is in other parenting styles except the democratic style and never have the genetic screening before birth.And children who with aggressive behavior may co-occur with other behavior problems.
10.Relationship Between Serum Levels of High Sensitivity Cardiac Troponin T and the Severity of Coronary Lesions in Patients With Stable Coronary Artery Disease
Minglin GU ; Xiaoming YAO ; Zhihua WANG ; Jiuping YIN ; Shengyong YU ; Lixing WU
Chinese Circulation Journal 2016;31(6):559-563
Objective: To investigate the relationship between serum levels of high sensitivity cardiac troponin T (hs-cTnT) and the severity of coronary lesions in patients with stable coronary artery disease (SCAD). Methods: A total of 450 SCAD patients with coronary angiography (CAG) conifrmed diagnosis in our hospital were studied, and serum levels of hs-cTnT were examined at 3 days prior CAG in all patients. Based on tertiles of Gensini score, the patients were divided into 3 groups: Low score group,n=153 patients with Gensini score<14, Intermediate score group, n=145 patients with Gensini score at 14-28 and High score group,n=152 patients with Gensini score>28. The relationships between Gensini score and hs-cTnT levels were analyzed among 3 groups. The optimal cut-off value of hs-cTnT for predicting high Gensini score and the need of revascularization were studied by ROC curve, the relationships between hs-cTnT and high Gensini score, the need of revascularization were further detected by Logistic regression analysis. Results: The median values (25%-75%) of hs-cTnT in Low score group, Intermediate score group and High score group were 6.72 (4.20, 8.93) pg/ml, 7.90 (5.74, 12.68) pg/ml and 14.99 (10.26, 24.30) pg/ml respectively, allP<0.01. ROC curve analysis indicated that the area under curve (AUC) of hs-cTnT for predicting high Gensini score was 0.837 (95% CI 0.803-0.874), for the need of revascularization was 0.772 (95% CI 0.728-0.817); the best cut-off value of hs-TnT for predicting high Gensini score was 10.04 pg/ml and for the need of revascularization was 8.56 pg/ml. Logistic regression analysis suggested that with adjusted age, gender, the history of hypertension, diabetes, smoking, blood levels of creatinine, LDL-C and hs-CRP, hs-cTnT was still an independent predictor for high Gensini score (OR=1.13, 95% CI 1.06-1.20,P<0.001) and for the need of revascularization (OR=1.19, 95% CI 1.14-1.24,P<0.001). Conclusion: Serum level of hs-cTnT has been related to severity of coronary lesions in SCAD patients, hs-cTnT might be used as one of the pre-operative predictor for severe coronary disease and for the need of revascularization.

Result Analysis
Print
Save
E-mail